maraviroc (Selzentry, Celsentri)

DRUG2 trials

Sponsors

ViiV Healthcare, Chinese University of Hong Kong

Conditions

Human Immunodeficiency Virus (HIV) InfectionMyositis

Phase 1

Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers

CompletedNCT00821535

ViiV HealthcareHuman Immunodeficiency Virus (HIV) Infection

Start: 2009-02-28End: 2009-05-31Updated: 2010-11-16

Phase 4

Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies

Not yet recruitingNCT07668505

Chinese University of Hong KongMyositis

Start: 2026-09-01End: 2029-08-31Target: 10Updated: 2026-06-30